A Phase I/II, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and efficacy of GB261 in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia.

  • Kenealy, Melita (Primary Chief Investigator (PCI))
  • Spence, Anne (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date21/02/22 → 31/12/24

Keywords

  • Malignant Haematology
  • Clinical trial

Clinical Trial Phase

  • Phase I
  • Phase II